Latest & greatest articles for rheumatoid arthritis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rheumatoid arthritis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rheumatoid arthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rheumatoid arthritis

181. Baricitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V

Baricitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.8 of the dossier assessment Baricitinib (Rheumatoide Arthritis) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 29 June 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-14 (...) Baricitinib (rheumatoid arthritis) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-14 Version 1.0 Baricitinib (rheumatoid arthritis) 29 June 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Baricitinib (rheumatoid arthritis) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

182. Venous thromboembolism and risk of cancer in patients with rheumatoid arthritis

Venous thromboembolism and risk of cancer in patients with rheumatoid arthritis Essentials Can venous thromboembolism (VTE) in rheumatoid arthritis (RA) patients be marker of cancer? RA patients with VTE and comparison cohorts from population-based registries were compared. Increased risk of cancer in RA patients with VTE during the first year of VTE was observed. Risk of cancer in RA patients was increased also during the longer period following VTE.Background It is unknown whether venous (...) thromboembolism (VTE) in rheumatoid arthritis (RA) patients can be a marker of occult cancer. Objectives To examine risk of cancer subsequent to VTE among RA patients compared with risk of cancer in an RA cohort without VTE and in a general population without RA and without VTE. Patients/Methods All RA patients with a first-time diagnosis of VTE (index date) during 1978-2013 and comparison cohorts were identified from population-based registries in Denmark. Results We identified three cohorts: 2497 RA

2017 EvidenceUpdates

183. Adalimumab (Cyltezo) - Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Hidradenitis Suppurativa, Psoriasis, Ankylosing Spondylitis, Uveitis

Adalimumab (Cyltezo) - Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Hidradenitis Suppurativa, Psoriasis, Ankylosing Spondylitis, Uveitis 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2017. Reproduction is authorised provided (...) Control QTPP Quality Target Product Profile RA Rheumatoid arthritis RF Rheumatoid factor RH Relative Humidity RLCA Response Level Correlation Assay RPN Risk Priority Number RPP Reference Product Pool RT Room Temperature s.c. Subcutaneous SAF Safety analysis set SCB Safety Cell Bank SD Standard deviation SPR Surface Plasmon Resonance t1/2 Terminal half-life of the analyte in plasma TEM Transmission electron microscopy tmax Time from (last) dosing to the maximum measured concentration in plasma TNF

2017 European Medicines Agency - EPARs

184. Sirukumab (Plivensia) - rheumatoid arthritis

Sirukumab (Plivensia) - rheumatoid arthritis 26 October 2017 Dr. Tomas Salmonson Chair of Committee for Medicinal Products for Human Use European Medicines Agency 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Subject: Withdrawal of Plivensia (sirukumab), 50 mg, solution for injection, pre-filled syringe and pre-filled pen - EMEA/H/C/004165/0000 Dear Dr. Salmonson We would like to inform you that, at this point of time, Janssen-Cilag International NV has taken the decision (...) to withdraw the application for Marketing Authorisation of Plivensia (sirukumab), 50 mg, solution for injection, pre-filled syringe and pre-filled pen, which was intended to be used for the treatment of moderately to severely active rheumatoid arthritis in adult patients. This withdrawal is based on the following reason: The Company made a global strategic decision to prioritize other assets in our portfolio, given the need for additional clinical data that would result in significant delays to patient

2017 European Medicines Agency - EPARs

185. The clinical effectiveness and cost-effectiveness of treat-to-target strategies in rheumatoid arthritis: a systematic review and cost-effectiveness analysis

The clinical effectiveness and cost-effectiveness of treat-to-target strategies in rheumatoid arthritis: a systematic review and cost-effectiveness analysis The clinical effectiveness and cost-effectiveness of treat-to-target strategies in rheumatoid arthritis: a systematic review and cost-effectiveness analysis Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found (...) . Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} There is some support for treat to target in rheumatoid arthritis, particularly in early stages, or for patients with disease duration < 5 years; however, it remains unclear which elements are important. {{author}} {{($index , , , , , , , , & . Allan Wailoo 1, * , Emma S Hock 1 , Matt Stevenson 1

2017 NIHR HTA programme

186. Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study (Full text)

Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study 'REASSURE' (NCT01377012), a phase 3 study, evaluated the efficacy and safety of secukinumab in patients with active rheumatoid arthritis (RA) who had an inadequate response to, or intolerance of, tumor necrosis factor inhibitors (TNF-inhibitors).A total of 637 patients were randomized (1:1:1) to receive intravenous secukinumab 10 mg/kg (baseline, weeks 2 and 4

2017 Rheumatology and therapy PubMed

187. Physical activity and sedentary behavior in patients with systemic lupus erythematosus and rheumatoid arthritis (Full text)

Physical activity and sedentary behavior in patients with systemic lupus erythematosus and rheumatoid arthritis Patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are at increased risk of cardiovascular disease (CVD). As sedentary behavior and lack of physical activity are known cardiovascular risk factors, we compared habitual activity between SLE patients, RA patients, and healthy control participants.For this cross-sectional study, RA and SLE patients were

2017 Open access rheumatology : research and reviews PubMed

188. Mortality in Italian patients with rheumatoid arthritis: evidence for a low mortality rate from cancer and infections in patients followed up at a tertiary center (Full text)

Mortality in Italian patients with rheumatoid arthritis: evidence for a low mortality rate from cancer and infections in patients followed up at a tertiary center Mortality in patients with rheumatoid arthritis (RA) has never been investigated in Italy. This study is devoted to investigating all the distinct causes of mortality in Italian RA patients.Clinical charts of patients consecutively admitted to an Italian tertiary center, from January 1, 2008 to December 31, 2014, were reviewed (...) by the National Institute of Statistics was observed. All-cause and neoplasm IMRs in our series were found to be significantly lower than that reported in the Norfolk Arthritis Registry, while no difference was detected in cardiovascular (CV) mortality. On the other hand, all causes and CV SMRs in our series were found to be higher than that reported in the general Italian population, while cancer and infectious SMRs were found to be lower.In our series, RA patients had an increased all-cause mortality

2017 Open access rheumatology : research and reviews PubMed

189. Promonitor for monitoring response to biologics in rheumatoid arthritis

Promonitor for monitoring response to biologics in rheumatoid arthritis Promonitor for monitoring response to biologics Promonitor for monitoring response to biologics in rheumatoid arthritis in rheumatoid arthritis Medtech innovation briefing Published: 27 October 2017 nice.org.uk/guidance/mib126 pathways Summary Summary The technology technology described in this briefing is Promonitor. It is used to monitor response to biologic therapies. The inno innovativ vative aspect e aspect (...) is that each sample only needs to be run once, potentially allowing for a higher throughput of tests. The intended place in ther place in therap apy y would be in addition to current methods of monitoring drug response in people with rheumatoid arthritis. The main points from the e main points from the evidence vidence summarised in this briefing are from 4 prospective studies (2 in Europe and 2 in Asia) and 1 study comparing 3 devices, including a total of 495 adults in specialist centres. They show

2017 National Institute for Health and Clinical Excellence - Advice

190. Initial Serological Response after Prime-boost Pneumococcal Vaccination in Rheumatoid Arthritis Patients: Results of a Randomized Controlled Trial

Initial Serological Response after Prime-boost Pneumococcal Vaccination in Rheumatoid Arthritis Patients: Results of a Randomized Controlled Trial To evaluate the initial serological responses to pneumococcal vaccination with the 13-valent protein-conjugated pneumococcal vaccine (PCV13) followed by the 23-valent polysaccharide pneumococcal vaccine (PPV23) among patients with rheumatoid arthritis (RA) treated with biological disease-modifying antirheumatic drugs (bDMARD) according to dosing

2017 EvidenceUpdates

191. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden (Full text)

Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden Considering the widespread and increasing use of biological immunomodulators (biological disease-modifying antirheumatic drugs [bDMARDs]) to treat chronic inflammatory conditions, and the concern that immunomodulation may alter cancer risk and progression, the limited available data on use (...) of these therapies as used in clinical practice and cancer risks are a concern.To assess the risk of incident malignant neoplasms in patients with rheumatoid arthritis (RA) treated with bDMARDs.This was a national register-based prospective cohort study of the public health care system in Sweden from 2006 to 2015. Cohorts of patients with RA initiating treatment with tocilizumab (n = 1798), abatacept (n = 2021), and rituximab (n = 3586), a tumor necrosis factor inhibitor (TNFi) as first-ever (n = 10 782

2017 EvidenceUpdates PubMed

192. Mortality following new-onset Rheumatoid Arthritis: has modern Rheumatology had an impact?

Mortality following new-onset Rheumatoid Arthritis: has modern Rheumatology had an impact? To investigate if, and when, patients diagnosed with rheumatoid arthritis (RA) in recent years are at increased risk of death.Using an extensive register linkage, we designed a population-based nationwide cohort study in Sweden. Patients with new-onset RA from the Swedish Rheumatology Quality Register, and individually matched comparators from the general population were followed with respect to death

2017 EvidenceUpdates

193. A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis (Full text)

A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis In disease-modifying antirheumatic drug-naive patients with early rheumatoid arthritis (RA) who had achieved sustained low disease activity (a Disease Activity Score in 28 joints using the erythrocyte sedimentation rate of ≤3.2 at both week 40 and week 52) after 1 year of treatment with certolizumab pegol (CZP) at a standard dose (200 mg (...) disability index score of ≤0.5; 71.4% and 70.6% of patients, respectively, versus 57.0%). Safety profiles were similar between all groups, with no new safety signals identified for continuing CZP to week 104. No deaths were reported.The study failed to meet its primary end point. However, there were no clinically meaningful differences between the standard and reduced frequency doses of CZP plus MTX; both controlled RA more effectively than stopping CZP.© 2017 The Authors. Arthritis & Rheumatology

2017 EvidenceUpdates PubMed

194. Sarilumab for moderate to severe rheumatoid arthritis

Sarilumab for moderate to severe rheumatoid arthritis Sarilumab for moder Sarilumab for moderate to se ate to sev vere ere rheumatoid arthritis rheumatoid arthritis T echnology appraisal guidance Published: 1 November 2017 nice.org.uk/guidance/ta485 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Sarilumab for moderate to severe rheumatoid arthritis (TA485) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 22Contents Contents 1 Recommendations 4 2 The technology 6 3 Committee discussion 7

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

195. Case series: Monoarticular rheumatoid arthritis (Full text)

Case series: Monoarticular rheumatoid arthritis Monoarticular presentation of rheumatoid arthritis is infrequent and has been previously reported to involve large joints such as the hip and knee joints. Here we report a case series of four patients presenting to the University of Michigan in 2015 with monoarticular rheumatoid arthritis, one with small and three with large joint involvement.In total, four patients with monoarticular rheumatoid arthritis were treated in the Division (...) of Rheumatology, University of Michigan. All the patients were retrospectively reviewed with permission from our Institutional Review Board; informed consent was provided by the patients for enrollment in a clinical trial for patients with rheumatoid arthritis. All the patients were assessed using the 2010 ACR/EULAR classification criteria for rheumatoid arthritis.All the patients presented with monoarthritis; three patients had large joint involvement and one had small joint involvement. Serologies were

2017 European journal of rheumatology PubMed

196. Tocilizumab (RoACTEMRA) [subcutaneous injection with an auto injector device] for adult patients with moderate to severe active rheumatoid arthritis - after DMARD failure

Tocilizumab (RoACTEMRA) [subcutaneous injection with an auto injector device] for adult patients with moderate to severe active rheumatoid arthritis - after DMARD failure Tocilizumab (RoACTEMRA) [subcutaneous injection with an auto injector device] for adult patients with moderate to severe active rheumatoid arthritis – after DMARD failure | Innovation Observatory toggle menu Menu Search View All Filter by Speciality Filter by Year Filter by Category This search function provides links (...) to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders. > > > Tocilizumab (RoACTEMRA) [subcutaneous injection with an auto injector device] for adult patients with moderate to severe active rheumatoid arthritis – after DMARD failure Tocilizumab (RoACTEMRA) [subcutaneous injection with an auto injector

2017 NIHR Innovation Observatory

197. Adalimumab impact on fatigue measured by FACIT-F: a study of rheumatoid arthritis patients in Saudi Arabia (Full text)

Adalimumab impact on fatigue measured by FACIT-F: a study of rheumatoid arthritis patients in Saudi Arabia The objective of the study was to assess the effectiveness of adalimumab as a treatment for fatigue in patients with rheumatoid arthritis (RA).Fatigue was monitored in patients with RA who were already on an adalimumab treatment regimen. Fatigue, general well-being, comorbidities, and disease activity were measured at baseline and ~8, 16, and 24 weeks, thereafter.Significant reductions

2017 Open access rheumatology : research and reviews PubMed

198. Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial (Full text)

Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial High adalimumab serum concentrations do not result in better response in patients with rheumatoid arthritis (RA), suggesting overexposure. We investigated whether patients with adalimumab concentrations >8 µg/mL can prolong their dosing interval by 50% without a clinically relevant change in disease activity.Consecutive

2017 EvidenceUpdates PubMed

199. [Tofacitinib (rheumatoid arthritis) - benefit assessment according to õ35a Social Code Book V]

[Tofacitinib (rheumatoid arthritis) - benefit assessment according to õ35a Social Code Book V] Tofacitinib (Rheumatoide Arthritis): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A17-18 [Tofacitinib (rheumatoid arthritis) - benefit assessment according to §35a Social Code Book V] Tofacitinib (Rheumatoide Arthritis): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A17-18 [Tofacitinib (rheumatoid arthritis) - benefit assessment according to §35a Social Code Book V (...) ] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Tofacitinib (Rheumatoide Arthritis): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A17-18. [Tofacitinib (rheumatoid arthritis) - benefit assessment

2017 Health Technology Assessment (HTA) Database.

200. Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial (Full text)

Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial To assess the efficacy and safety of initial COBRA-light vs COBRA therapy in RA patients after a 4-year follow-up period.In the COBRA-light trial, 162 consecutive patients with recent-onset RA were randomized to either COBRA-light (prednisolone and MTX) or COBRA therapy (prednisolone, MTX and SSZ) for 1 year. After 1 year, treatment was continued without

2017 EvidenceUpdates PubMed